Retacrit will be priced 57.1% below the Wholesale Acquisition Cost (WAC) of Procrit and 33.5% below the WAC of Epogen, at $11.03 per 1000 Units/mL. In addition, Retacrit is indicated for the reduction ...
The FDA has approved Pfizer’s biosimilar drug, Retacrit, a cut price competitor Amgen and Johnson & Johnson's bone marrow stimulating drug epoetin alfa. Retacrit (epoetin alfa-epbx), is a biosimilar ...
FDA LOGO BLUE The approval of Retacrit was based on a review of evidence that included human pharmacokinetic/pharmacodynamic data and clinical immunogenicity data ...
Please provide your email address to receive an email when new articles are posted on . The FDA today approved epoetin alfa-epbx, the first epoetin alfa biosimilar, for the treatment of anemia caused ...
Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information ...
EXTON, Pa., July 31, 2018 /PRNewswire/ -- Plagued by regulatory delays, the FDA finally granted approval for Retacrit in May 2018, making it the first biosimilar erythropoietin-stimulating agent (ESA) ...
Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, announced today results from a post-marketing study of the company's European biosimilar epoetin, ...
Hospira, Inc. HSP presented data from two studies on a proposed biosimilar, Retacrit (Epoetin Hospira), at the National Kidney Foundation spring meeting. The drug is a proposed biosimilar to Amgen Inc ...
After experiencing slow uptake for its first biosim launch, Pfizer isn’t giving up on the budding field. On Wednesday, the drugmaker introduced its third biosim, and second in two months, launching ...
The US Food and Drug Administration (FDA) has approved the first biosimilar erythropoiesis-stimulating agent. The reference product is epoetin alfa (Epogen/Procrit, Amgen). The new biosimilar is ...
CHICAGO, Dec 19 (Reuters) - Hospira Inc said on Wednesday it won European approval to sell Retacrit, also known as epoetin zeta, a generic version of erythropoietin, as a treatment for anemia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results